Overview

Indacaterol EfectIveness In COPD Patients With Tuberculosis History

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals